Durolane
Stage
Acquired Unit | AcquiredAbout Durolane
Durolane is a product that helps relieve the pain of osteoarthritis (OA) in a variety of joints. Osteoarthritis (OA) is the most common cause of knee and hip pain. OA can affect young and old alike but more often affects people over the age of 40 - predominantly those that have been active and those that still are.
Missing: Durolane's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Durolane's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Latest Durolane News
May 2, 2022
Durham, North Carolina, UNITED STATES DURHAM, N.C., May 02, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, has agreed to a nationwide contract with Cigna® commercial plans. Beginning July 1, 2022, Cigna® commercial plan members will have access to both DUROLANE and GELSYN-3 , to treat knee osteoarthritis (OA) pain. DUROLANE, is a single-injection and GELSYN-3, is a three-injection hyaluronic acid (HA)-based joint-fluid treatment for patients. Durolane will be exclusive to all Cigna patients while Gelsyn-3 will be one of two multi-injection HA products under contract. OA involves the breakdown, or degeneration, of cartilage and the synovial fluid that cushions and lubricates joint tissues. Injection treatments of HA-based products, such as DUROLANE and GELSYN-3, help manage knee OA pain. “We are pleased and excited DUROLANE and GELSYN-3 are among the preferred options available to Cigna® members and physicians,” said Tim Donovan, Vice President of Market Access & Health Economics for Bioventus. “Both now have access to two safe HA products that are proven to provide relief from knee OA pain.” About Bioventus Bioventus delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. The Innovations for Active Healing from Bioventus include offerings for pain treatment, restorative therapies and surgical solutions. Built on a commitment to high quality standards, evidence-based medicine and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide. For more information, visit www.bioventus.com , and follow the Company on LinkedIn and Twitter . Bioventus, the Bioventus logo, GELSYN-3 and DUROLANE are registered trademarks of Bioventus LLC. Media Contact:
Durolane Frequently Asked Questions (FAQ)
Where is Durolane's headquarters?
Durolane's headquarters is located at Taurusavenue 31, Hoofddorp.
What is Durolane's latest funding round?
Durolane's latest funding round is Acquired Unit.
Who are the investors of Durolane?
Investors of Durolane include Bioventus.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.